| Prev Close | 1.77 |
| Open | 1.79 |
| Day Low/High | 1.76 / 1.80 |
| 52 Wk Low/High | 2.37 / 5.81 |
| Volume | 258.02K |
| Avg Volume | 741.60K |
| Exchange | NASDAQ |
| Shares Outstanding | 39.36M |
| Market Cap | 72.02M |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
First Week of January 2018 Options Trading For pSivida (PSDV)
Investors in pSivida Corp saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
PSivida Announces 13 New Patents Issued Or Allowed
U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™
Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle
Results to Form Part of Planned Applications for Marketing Approvals in EU and US
PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer
Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience
PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)
Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit
Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy
Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society
PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility
Plan to Facilitate Product Development and Reduce Operating Expenses
Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve
Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology
